Get the Stockscreener App
1.28
1.59%
0.02
After Hours:
1.28
Geron Corp stock is traded at $1.28, with a volume of 6.75M.
It is up +1.59% in the last 24 hours and down -17.42% over the past month.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
6.75M
Relative Volume:
0.37
Market Cap:
$821.15M
Revenue:
$183.88M
Net Income/Loss:
$-85.78M
P/E Ratio:
-9.9456
EPS:
-0.1287
Net Cash Flow:
$-110.95M
1W Performance:
-0.78%
1M Performance:
-17.42%
6M Performance:
+14.29%
1Y Performance:
-13.51%
1-Day Range:
$1.25
$1.29
1-Week Range:
$1.20
$1.305
52-Week Range:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.28 | 808.32M | 183.88M | -85.78M | -110.95M | -0.1287 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Geron Corporation’s SWOT analysis: biotech stock faces sales headwinds - Investing.com
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo! Finance Canada
Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus - AD HOC NEWS
Five new Geron hires receive options for 333,750 shares - Stock Titan
Shareholders of Geron Corporation Should Contact The Gross Law F - GuruFocus
GERN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Deep Track (GERN) reports 31.7M shares, 4.95% ownership (May 2026) - Stock Titan
GERN Stock Chart | GERON CORP (NASDAQ:GERN) - ChartMill
Geron reports Q1 revenue growth and updates on blood cancer drug progress. - Pluang
Geron Corporation Announces Positive Real-World Evidence Study of RYTELO® in Lower-Risk Myelodysplastic Syndromes Ahead of EHA 2026 Presentations - Quiver Quantitative
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026 - ChartMill
RYTELO study: 37.5% of transfusion-dependent went 8 weeks transfusion-free - Stock Titan
Is Geron (GERN) One of the Best US Stocks Under $5 to Buy? - Insider Monkey
10 Best US Stocks Under $5 to Buy - Insider Monkey
Geron Corporation (NASDAQ:GERN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
1GERN.MI Stock Price, Quote & Chart | GERON CORP (BIT:1GERN) - ChartMill
Soleus group discloses 41.51M GERN shares (6.5%) — Soleus/Guy Levy - Stock Titan
A Look At Geron (GERN) Valuation After Q1 Results And Reaffirmed 2026 Guidance - Yahoo Finance
Geron Corporation (NASDAQ:GERN) Q1 2026 Earnings Call Transcript - Insider Monkey
Geron Corporation (NASDAQ:GERN): Is Breakeven Near? - Moomoo
Geron (GERN) Q1 2026 Earnings Call Transcript - AOL.com
Geron Corporation Q1 2026 Financial Results: Revenue, Net Loss, and SEC Filing Insights - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Geron Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
Geron: Q1 Earnings Snapshot - theheraldreview.com
[10-Q] GERON CORP Quarterly Earnings Report - Stock Titan
Geron Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Geron Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp. (NASDAQ:GERN) Beats Q1 Estimates as RYTELO Sales Momentum Continues - ChartMill
Geron Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
GERON ($GERN) Releases Q1 2026 Earnings - Quiver Quantitative
$341M cash and $51.8M Q1 sales keep Geron on its 2026 path - Stock Titan
MSN Money - MSN
Geron earnings loom: Can RYTELO revenue sustain commercial momentum? By Investing.com - Investing.com Canada
Geron earnings loom: Can RYTELO revenue sustain commercial momentum? - Investing.com
Geron executives line up two healthcare investor conference talks - Stock Titan
Earnings Preview: Geron to Report Financial Results Pre-market on May 06 - 富途牛牛
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Geron (GERN) to Release Earnings on Wednesday - MarketBeat
Geron (NASDAQ:GERN) Stock Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal Officer - Insider Monkey
Geron (GERN) Receives a Buy from TD Cowen - The Globe and Mail
GERN Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (NASDAQ:GERN) - ChartMill
Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
Geron sets May 6 financial update with webcast before market open - Stock Titan
GERN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Form 4Statement of changes in beneficial ownership of securities - ADVFN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):